Annualized Incidence and Spectrum of Illness from an Outbreak Investigation of Bell’s PalsyMorris A.M.a · Deeks S.L.b,e · Hill M.D.c · Midroni G.c · Goldstein W.C.d · Mazzulli T.a · Davidson R.a · Squires S.G.e,f · Marrie T.g · McGeer A.a · Low D.E.a
aMount Sinai Hospital, Department of Microbiology, University of Toronto, bOntario Ministry of Health, Public Health Branch, cSt. Michael’s Hospital, Division of Neurology, University of Toronto, Toronto, Ont., dYork Central Hospital, Department of Medicine, Richmond Hill, Ont., eLaboratory Field Epidemiology Training Program, Laboratory Centre for Disease Control, Ottawa, Ont., fNova Scotia Department of Health, and gQueen Elizabeth II Hospital, Department of Medicine, Dalhousie University, Halifax, N.S., Canada
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: There are limited clinical and epidemiological data on patients diagnosed with Bell’s palsy. While investigating an apparent clustering of Bell’s palsy, we sought to characterize the spectrum of illness in patients with this diagnosis. Methods: A telephone survey of persons with idiopathic facial (Bell’s) palsy in the Greater Toronto Area (GTA, population = 4.99 million) and Nova Scotia (population = 0.93 million) from August 1 to November 15, 1997 collected information on subject demographics, neurological symptoms, constitutional symptoms, medical investigation and management. Information regarding potential risks for exposure to infectious agents, past medical history, and family history of Bell’s palsy was also collected. Subjects with other secondary causes of facial palsy were excluded. Results: In the GTA and Nova Scotia, 222 and 36 patients were diagnosed with idiopathic facial (Bell’s) palsy, respectively. The crude annualized incidence of Bell’s palsy was 15.2 and 13.1 per 100,000 population in the GTA and Nova Scotia, respectively. There was no temporal or geographical clustering, and symptomatology did not differ significantly between the two samples. The mean age was 45 years, with 55% of subjects being female. The most common symptoms accompanying Bell’s palsy were increased tearing (63%), pain in or around the ear (63%), and taste abnormalities (52%). A significant number of patients reported neurological symptoms not attributable to the facial nerve. Conclusion: No clustering of cases of Bell’s palsy was observed to support an infectious etiology for the condition. Misdiagnosis of the etiology of facial weakness is common. Patients diagnosed with Bell’s palsy have a variety of neurological symptoms, many of which cannot be attributed to a facial nerve disorder.
© 2002 S. Karger AG, Basel
- Savettieri G, Salemi G, Rocca WA, Meneghini F, Santangelo R, Morgante L, et al: Incidence and lifetime prevalence of Bell’s palsy in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Acta Neurol Scand 1996;94:71–75.
- Katusic SK, Beard CM, Wiederholt WC, Bergstralh EJ, Kurland LT: Incidence, clinical features, and prognosis in Bell’s palsy, Rochester, Minnesota, 1968–1982. Ann Neurol 1986;20:622–627.
- Leibowitz U: Epidemic incidence of Bell’s palsy. Brain 1969;92:109–114.
- Adour KK, Wingerd J: Nonepidemic incidence of idiopathic facial paralysis. Seasonal distribution of 419 cases in three years. JAMA 1974;227:653–654.
- Burken M, May L, Groves C, Trivedi L, Scott L, Israel E: Cluster of Bell’s palsy cases found among hospital employees. Clin Infect Dis 1992;15:381–382.
- Frumkin H, Horowitz M, Jabre JF, Payton M, Kantrowitz W: An investigation of a workplace cluster of Bell’s palsy. J Occup Med 1992;34:1064–1070.
- Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N: Bell palsy and herpes simplex virus: Identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996;124:27–30.
- Adour KK, Byl FM, Hilsinger RLJ, Kahn ZM, Sheldon MI: The true nature of Bell’s palsy: Analysis of 1,000 consecutive patients. Laryngoscope 1978;88:787–801.
Adour KK: Herpes simplex polyganglionitis. The great masquerader. Arch Intern Med 1979;139:1339–1340.
- Sandstedt P, Hyden D, Odkvist L: Bell’s palsy – part of a polyneuropathy? Acta Neurol Scand 1981;64:66–73.
- McKeever P, Proctor B, Proud G: Cranial nerve lesions in Bell’s palsy. Otolaryngol Head Neck Surg 1987;97:326–327.
Statistics Canada – Demography Division: Annual Demographic Statistics, 1998. Ottawa, 1999.
- Rotbart HA: Enzymatic RNA amplification of the enteroviruses. J Clin Microbiol 1990;28:438–442.
- Hill MD, Midroni G, Goldstein W, Morris A, Deeks S, Low D: The spectrum of electrophysiological abnormalities in Bell’s palsy. Can J Neurol Sci 2001;28:130–133.
Bland M: Significance tests; in Anonymous: An Introduction to Medical Statistics, ed 2. Oxford, Oxford Medical Publications, 1995, pp 133–151.
- Byl FM, Adour KK: Auditory symptoms associated with herpes zoster or idiopathic facial paralysis. Laryngoscope 1977;87:372–379.
- Adour K, Wingerd J, Doty HE: Prevalence of concurrent diabetes mellitus and idiopathic facial paralysis (Bell’s palsy). Diabetes 1975;24:449–451.
- Devriese PP, Schumacher T, Scheide A, de Jongh RH, Houtkooper JM: Incidence, prognosis and recovery of Bell’s palsy. A survey of about 1,000 patients (1974–1983). Clin Otolaryngol 1990;15:15–27.
- Brandenburg NA, Annegers JF: Incidence and risk factors for Bell’s palsy in Laredo, Texas: 1974–1982. Neuroepidemiology 1993;12:313–325.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.